Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
Dissolution Methods for Long-acting Periodontal Drug Products (U01)
There is a lack of compendial or biorelevant in vitro drug release assays for long-acting periodontal dosage forms.
These products include biodegradable microspheres, in situ forming implants and matrix tablets.
The purpose of this study is to develop a bio-relevant dissolution method for a long-acting periodontal dosage form and to identify the drug product's key physicochemical attributes that affect the drug dissolution behavior and bioavailability.
The results from this study will help the FDA in developing recommendations to determine bioequivalence of generic long-acting periodontal drug products.
These products include biodegradable microspheres, in situ forming implants and matrix tablets.
The purpose of this study is to develop a bio-relevant dissolution method for a long-acting periodontal dosage form and to identify the drug product's key physicochemical attributes that affect the drug dissolution behavior and bioavailability.
The results from this study will help the FDA in developing recommendations to determine bioequivalence of generic long-acting periodontal drug products.
Who's Eligible
Obtain Full Opportunity Text:
Full Announcement of RFA-FD-15-007 on NIH Guide for Grants and Contracts
Additional Information of Eligibility:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are eligible to apply.
Foreign components, as defined in the HHS Grants Policy Statement, are allowed.
Full Opportunity Web Address:
Contact:
Agency Email Description:
Agency Email:
lisa.ko@fda.hhs.gov
Date Posted:
2015-02-17
Application Due Date:
2015-04-27
Archive Date:
2015-05-27
